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NOAC Non-vitamin K antagonist oral anticoagulant
NSTEMI Non-ST-segment elevation myocardial infarction
PCI Percutaneous coronary intervention
PDA Posterior descending artery
PEGASUS-
TIMI 54
Prevention of Cardiovascular Events in Patients With
Prior Heart Attack Using Ticagrelor Compared to
Placebo on a Background of Aspirin-Thrombolysis in
Myocardial Infarction 54
PIONEER-
AF-PCI
Rivaroxaban and a dose- adjusted oral vitamin K
antagonist treatment strategy in subjects with atrial
fibrillation who undergo percutaneous coronary
intervention
PLATO Platelet Inhibition and Patient Outcomes
PPI Proton pump inhibitor
PRECISE-
DAPT
PREdicting bleeding Complications In patients under-
going Stent implantation and subsEquent Dual Anti
Platelet Therapy
PRODIGY Prolonging Dual Antiplatelet Treatment After
Grading Stent- Induced Intimal Hyperplasia Study
RCA Right coronary artery
ST Stent thrombosis
STS Society of Thoracic Surgery
STEMI ST-segment elevation myocardial infarction
TIMI Thrombolysis In Myocardial Infarction
t-PA Tissue plasminogen activator
TRITON-
TIMI 38
TRial to assess Improvement in Therapeutic
Outcomes by optimizing platelet inhibitioN with
prasugrel–Thrombolysis In Myocardial Infarction 38
TTE Transthoracic echocardiography
ULN Upper limit of normal
VASP Vasodilator-stimulated phosphoprotein
VKA Vitamin K antagonist
Case #1 Navigating between the
risks of stent thrombosis and
major haemorrhage
A 77-year-old male presented with inferolateral ST-segment eleva-
tion myocardial infarction (STEMI) complicated by transient com-
plete heart block and syncope, and underwent successful
thrombolysis within two hours of symptom onset. He was immedi-
ately loaded with aspirin and clopidogrel and was brought to the
catheterization laboratory for coronary angiography, which showed
no flow-limiting plaques in the left system (Figure 1A) but the pres-
ence of a thrombotic non-occlusive coronary stenosis in the distal
right coronary artery (RCA) (Figure 1B), which was treated with
implantation of a bare-metal stent (BMS) (4 x 18 mm long, GenousVR
stent). In the morning after percutaneous coronary intervention
(PCI) and before the planned intake of dual antiplatelet therapy
(DAPT), the patient presented a sudden haematemesis followed by
melena. The ongoing major gastrointestinal (GI) bleeding was accom-
panied by haemodynamic instability and a drop in the haemoglobin
level to 8.5 g/dL, requiring intravenous (IV) fluids and red blood cell
concentrate transfusion. A decision was taken to stop both clopidog-
rel and aspirin, start IV proton pump inhibitor (PPI) and refer the
patient for an upper GI endoscopy, which identified and treated a
large Mallory-Weiss tear. Three hours after endoscopic intervention
(i.e. 39 hours after the bleeding episodes and after having skipped
two consecutive clopidogrel maintenance doses after the loading reg-
imen) the patient showed pulseless ventricular tachycardia termi-
nated by defibrillation but followed by third degree atrioventricular
block and again ST elevation in the inferior leads. The patient was
brought back to the catheterization laboratory. Angiography
revealed occlusion of the RCA, then treated using a thrombus aspira-
tion catheter device.
Comments from the Task Force
This case illustrates the multifactorial origin of stent thrombosis (ST)
and the interplay between major bleeding and acute thrombotic
state. Several aspects warrant further discussion.
- (i) The use of a slow-acting P2Y12 oral receptor inhibitor (clopidogrel)
in the context of a high thrombotic burden may account for a non-
optimal inhibition of this pathway (see chapter 3.6 in full text docu-
ment). In addition, fibrinolysis, severe anaemia and cardiogenic shock
may have potentiated platelet activation/aggregation. Yet, there is no
reassuring evidence on the safety of combining more potent P2Y12 oral
receptor inhibitors in patients who have received fibrinolysis, and the
decision in this case to administer clopidogrel is justifiable and in line
with current recommendations. The decision to interrupt both oral
antiplatelet drugs in the context of ongoing major bleeding may have
magnified platelet reactivity leading to ST.1
- (ii) Delayed interventional endoscopy precluding earlier oral re-
administration of oral antiplatelet drug may have also triggered the hae-
mostatic balance towards a prothrombotic state. It should be noted
that the European Society of Gastrointestinal Endoscopy (ESGE)
recently recommended very early (< 12 hours) upper GI endoscopy in
patients with high risk clinical features, namely haemodynamic instability
(e.g. tachycardia, hypotension) that persists despite adequate volume
replacement; in-hospital bloody emesis/nasogastric aspirate; or contra-
indication to the interruption of antiplatelet therapies or anticoagula-
tion.2 Therefore, an alternative treatment strategy would have been to
perform upper GI endoscopy more expeditiously to better control
bleeding and obtain a diagnosis while avoiding immediate discontinua-
tion of both antiplatelet agents or even allowing for continuation of
both agents.
- (iii) The need for red blood cell transfusion, which was clearly justified in
this case due to the presence of haemodynamic instability, may have
also favoured high platelet reactivity as a consequence of adenosine
diphosphate (ADP) release.3 The need for transfusion should always be
weighed against the established detrimental effect in terms of a possible
increase in ischaemic events, especially in patients with recent myocar-
dial infarction (MI).4
- (iv) Systematic administration of PPI is an effective preventive measure
in patients at risk of GI bleeds (see chapter 3.7 in full text document).5
This was the case here. The pharmacodynamic interaction observed
between clopidogrel and PPI has never been associated with any signifi-
cant adverse outcome effects.6
- (v) A final comment should be reserved for the type and timing of inter-
vention. BMS implantation is no longer supported by evidence and
guidelines. In case of successful thrombolysis, there is no evidence that
the patient should be immediately brought to the catheterization labo-
ratory while a delay of 3 - 12 hours is recommended.
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Case #2: Platelet function testing
in high-risk non-ST-elevation myo-
cardial infarction
A 70-year-old female with class 2 obesity (i.e. body mass index
>35 kg/m2) was admitted for a high-risk non-ST-segment elevation
myocardial infarction (NSTEMI). She underwent right carotid endar-
terectomy for asymptomatic disease four years earlier and was
known to have a 70% stenosis of the left internal carotid artery. Her
medical treatment included statin, angiotensin-converting enzyme
(ACE) inhibitor and aspirin. A diagnostic coronary angiogram was
performed the same day, and showed a 90% stenosis of the proximal
left anterior descending (LAD) coronary artery. The culprit lesion
was treated with coronary stenting after a loading dose of 300 mg
aspirin and 600 mg clopidogrel. Serial platelet function testing meas-
ures using multiplate electrode aggregometry were performed in the
following days (Figure 2) to assess on-treatment platelet reactivity.
This led to the switch from clopidogrel to ticagrelor on day 5 after
PCI by means of 180 mg loading dose followed by 90 mg b.i.d.
Measurements performed at three and six months follow-up indi-
cated an acceptable level of platelet reactivity according to the
threshold of the aggregometry device.
Comments from the Task Force
This clinical case merits further discussion.
- (i) First, this high-risk female presenting with NSTEMI in the context of a
known polyvascular disease should have been treated upfront with a
more potent P2Y12 receptor inhibitor instead of clopidogrel according
to the ESC guidelines (see chapter 3.6 in full text document). Ticagrelor
and prasugrel have demonstrated their superiority over clopidogrel in
acute coronary syndrome (ACS) patients and either of the two should
be first line treatment in this condition.
- (ii) Platelet reactivity assessment during P2Y12 inhibitor treatment iden-
tifies PCI-treated patients with a high on-treatment platelet reactivity
who are at higher risk for mortality and ST and patients with a low on-
treatment platelet reactivity who are at an increased risk for major
bleeding.7,8 However, randomized trials testing the hypothesis of the
clinical benefit of platelet function monitoring to adjust therapy failed to
show any clinical benefit.9–12 For these reasons, platelet function testing
is not recommended on a routine basis for tailoring DAPT after stenting
(see chapter 3.7 in full text document).
Case #3: Recurrent
gastrointestinal bleeding in a
patient on dual antiplatelet
therapy waiting for coronary
revascularization
A 52-year-old male with stable angina due to chronic total occlusion
(CTO) of the RCA and of the LAD (Figure 3A) underwent successful
recanalization of the RCA with three drug-eluting stents (DES)
(XienceVR ) (Figure 3B). He was then discharged on aspirin and ticagre-
lor and re-admitted for scheduled PCI of the LAD five months later.
Blood tests at admission showed profound anaemia related to iron
deficiency (haemoglobin 7.3g/dL; mean corpuscular volume 63.3 fL).
At further assessment, it was found that three months after the first
PCI the patient had been admitted for melena and DAPT was with-
held for one week.
The planned staged PCI of the LAD was postponed, the patient
was transfused with 2 units of blood and DAPT was discontinued.
Upper GI tract endoscopy was unremarkable whereas lower GI tract
endoscopy identified a solitary rectal ulcer. Therapy with oral esome-
prazole was initiated as a measure to prevent GI bleeding. The patient
was discharged on aspirin and ticagrelor after confirmation of a nega-
tive stool occult blood test and a haemoglobin level of 12.9 g/dL.
Recurrent anaemia occurred again three weeks later necessitating
BA
Figure 1 Urgent coronary angiography showing atherosclerosis
of the left coronary artery without significant stenosis (A) and a crit-
ical stenosis of the distal right coronary artery with presence of
thrombus (B).
Figure 2 Decision-making process for dual antiplatelet therapy
(DAPT) strategy selection in case #2. ADP test is for adenosine
diphosphate; ASPI test is for arachidonic acid; PCI = percutaneous
coronary intervention.
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once more DAPT interruption for one week and haemorrhoid clip-
ping. Upper endoscopy remained unremarkable and lower endos-
copy identified a healed rectal ulcer. Aspirin was then restarted on a
background of PPI and clopidogrel was introduced a month later after
repeated testing showing haemoglobin levels above 12 g/dL. PCI of
the LAD CTO was then successfully performed with three DES
(Figure 3C). The patient was discharged on aspirin and clopidogrel
together with PPI. Haemoglobin levels remained stable thereafter
and no further recurrent bleeding occurred.
Comments from the Task Force
The present case raises several points:
- (i) The selection of ticagrelor instead of clopidogrel for PCI in a patient
with stable coronary artery disease (CAD) merits discussion. The use
of ticagrelor or prasugrel is off-label in the setting of elective PCI/stable
CAD. ESC guidelines state that ticagrelor or prasugrel may be reason-
ably used in elective PCI in case of prior history of ST while on clopidog-
rel (see chapter 3.6 in full text document). Although in the patient
described the risk of ST was not negligible considering the complexity
of the PCI with multiple and overlapping stent implantation after recan-
alization of a CTO, no prior ST occurred to justify such an escalation of
therapy. It can be argued that the use of ticagrelor may have inappropri-
ately increased the bleeding risk as compared to clopidogrel.
- (ii) The duration of DAPT after elective PCI is also worth focusing on.13
The DAPT Focused Update recommends six months irrespective of
the stent type (see chapter 4.1 in full text document). In the case of high
risk of bleeding, this duration should be reduced to three months or to
one month if there is a safety concern.14 On the other hand, in the case
of complex PCI (which encompasses PCI for CTO), DAPT longer than
six months may be considered (see chapter 9.4 in full text document).
Before the first bleeding episode occurred, the a priori ischaemic risk
was likely greater than the bleeding hazard. The occurrence of bleeding
while on DAPT three months after the first PCI justifies DAPT discon-
tinuation and further diagnostic work-up in order to identify the bleed-
ing aetiology (as correctly performed three months later).
- (iii) Reintroduction of ticagrelor three months after an elective case
with on-treatment major bleeding during follow-up is questionable and
not supported by the data. De-escalation of the P2Y12 receptor block-
ade intensity with clopidogrel may have been more appropriate to
avoid recurrent bleeding.
- (iv) The fourth point to be discussed is treatment interruption in the
context of acute bleeding. GI tract bleeding is the first cause of major
bleeding and is associated with a better outcome as compared to bleed-
ing of unknown origin. Interventional endoscopy avoids complete inter-
ruption of DAPT (i.e. discontinuation of both antiplatelet agents), an
independent predictor of ST and mortality.15
- (v) The benefit of red blood cell transfusion should always be discussed
in the absence of haemodynamic compromise or when the patient tol-
erates chronic anaemia. Red blood cell transfusion has been shown to
be detrimental especially in patients with known CAD.4
- (vi) Finally, the patient management before proceeding to PCI of the
LAD is noteworthy. Postponing an elective intervention in the absence
of angina or angina symptoms until bleeding has resolved or been
treated and the patient can safely tolerate a DAPT regimen is
commendable.
A
B
C
Figure 3 Diagnostic angiogram showing occluded right coronary
artery (blue arrow) and occluded left anterior descending coronary
artery (yellow arrow) (A). Final result after first intervention with
implantation of three drug-eluting stents in the right coronary artery
(B). Final result after second intervention with implantation of three
drug-eluting stents in the left anterior descending coronary artery
(C).
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..Case #4: Recurrent left ventricle
thrombus after discontinuation of
oral anticoagulation
A 66-year-old man with a history of hypertension and diabetes pre-
sented with chest pain and inferior STEMI. In addition, an electrocar-
diogram (ECG) showed Q waves in the anterior leads. He reported
similar symptoms a month before. Coronary angiography showed
chronic occlusion of the mid-LAD (Figure 4A) and acute occlusion of
the mid-RCA, which was successfully treated with DES implantation.
Transthoracic echocardiography (TTE) showed left ventricular (LV)
inferior hypokinesia, and anterior and apical akinesia with a large
intraventricular thrombus adherent to the septo-apical and infero-
apical endocardium (Figure 4B). The LV ejection fraction (LVEF) was
37%. He was discharged on aspirin and clopidogrel for six months
combined with vitamin K antagonist (VKA) and PPI. Four months
after discharge, TTE showed an absence of LV thrombus (Figure 4C),
recovery of LVEF, but persistent LV apical-anterior and anterior aki-
nesia. VKA was then stopped. However, at six months’ follow-up
TTE showed a recurrence of apical thrombus in the absence of clini-
cal embolization. Oral anticoagulant (OAC) was resumed with
DAPT up to one year and clopidogrel was finally stopped after no
recurrent apical thrombus was demonstrated.
Comments from the Task Force
The case raises several points for discussion:
- (i) Type of stent in patients who have or may develop an indication for
concomitant OAC: the benefit of using a DES to prevent restenosis has
been questioned due to the increased risk of bleeding with long-term
triple antithrombotic therapy. The DAPT update guidelines have clearly
outlined that the choice of newer-generation DES vs. BMS in patients
requiring long-term anticoagulation is no longer controversial. Two
randomized trials have demonstrated the superiority of newer-
generation DES over BMS in high-bleeding risk patients who cannot tol-
erate long-term exposure to DAPT such as those needing chronic
OAC (see chapter 2.2 in full text document).14,16 This has been shown
in patients at high bleeding risk in whom long-term DAPT could not be
sustained.
- (ii) Duration of VKA therapy in case of mural thrombi: The 2017 ESC
STEMI guidelines state that in patients with LV thrombus, anticoagula-
tion should be administered for up to six months guided by repeated
imaging. In the present case, cessation of OAC may have been too early
given the persistent apical akinesia even if there was an LVEF improve-
ment. In addition, the absence of a bleeding event and the lack of
comorbidities or frailty features were supportive arguments for sus-
tained OAC.
- (iii) Duration of DAPT in the context of chronic OAC: the optimal dura-
tion of triple antithrombotic therapy is unknown especially in the con-
text of ACS. What is established is that patients exposed to triple
therapy should be considered at high bleeding risk. It seems that the
rate of bleeding events peaks within the first 30 days of initiation of tri-
ple therapy and is twice as high when compared with the rate of acute
coronary events including recurrent MI and ST.17 For these reasons,
duration of triple therapy should be minimized depending on bleeding
and ischaemic risks. In the present case, high-risk features of stent-
driven recurrent ischaemic events were absent (see Table 5 and chap-
ter 7.2 in full text document) and there were no unfavourable factors
that would plead against the combination of OAC and antiplatelet ther-
apy (see Table 6 and chapter 7.2 in full text document). For these rea-
sons, one month to a few month(s) of triple therapy would have been
reasonable.
- (iv) Cessation of antiplatelet therapy after one year: This is a pending issue
with no prospective evidence. According to the 2017 ESC consensus
document, all antiplatelet agents should be stopped after one year and
OAC maintained, unless the risk for recurrent ischaemic events is esti-
mated to be high.5 Given the low risk of coronary ischaemic recurrences
in the case described above, OAC alone seems justified.
Case #5: A heart and brain
emergency
A 52-year-old truck driver presented with anterior STEMI as the first
manifestation of CAD secondary to mid LAD occlusion, which was
treated with primary PCI and the implantation of a DES. Beyond the
mentioned LAD lesion, the coronary tree showed only minimal athe-
rosclerosis. The patient received oral aspirin 250 mg, ticagrelor
180 mg and enoxaparin 1 mg/kg as the anticoagulation regimen during
PCI. Because of post-procedural persisting pain thought to be due to
distal embolization, eptifibatide (10.7 ml x 2 boluses during PCI
A
B C
Figure 4 Chronic total occlusion of the mid left anterior
descending coronary artery (A). Evidence of ventricular thrombus
(yellow arrow) (B). Complete resolution of the apical thrombus in
its former position (yellow arrow) at four months’ follow-up (C).
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followed by 19.2 mL per hour infusion) was administered for a total of
10 hours, while DAPT was pursued. His cardiovascular risk factors
included previous smoking and overweight (body mass index 31 kg/
m2), while his cholesterol status was unknown. In addition, there was a
familial history of haemochromatosis and polycythaemia. His haemo-
globin was 16.9 g/dL, white blood cell count 9.4 x 109/L, platelets 155
x 109/L, and ferritin level 591 mg/L (upper limit of normal [ULN] 300);
troponin I level was raised from 0.144 to 91 ng/mL (ULN 0.04). Renal
function was normal. The initial clinical course was uneventful. A TTE
performed at day 2 showed a mild reduction in LV systolic function
(LVEF 52%) with apico-antero-lateral wall hypokinesia and an echo-
genic area in the apex suggestive of thrombus (Figure 5A-B). On day 3,
the patient complained about transient right eye vision disturbance,
mentioning that he was not able to see the television properly.
Immediate neurologic examination revealed an isolated right homony-
mous hemianopia. After excluding an intracranial haemorrhage with a
non-injected computed tomography (CT) scan, the stroke team per-
formed IV thrombolysis with tissue plasminogen activator (t-PA).
Antiplatelet agents were put on hold. Next day (day 4), visual symp-
toms recovered completely. Brain magnetic resonance imaging (MRI)
showed a small left occipital infarct with no haemorrhagic transforma-
tion (Figure 5C). Ticagrelor was replaced by clopidogrel 75 mg/day (no
loading dose) and aspirin discontinued. On day 5, both warfarin and
enoxaparin (1 mg/kg subcutaneous b.i.d. as a bridge until therapeutic
anticoagulation with warfarin was achieved) were started. At three
months’ follow-up, the patient remained asymptomatic and LV func-
tion returned to normal at TTE, which did not show imaging compati-
ble with intracavitary thrombus. Warfarin was stopped and aspirin
was added to clopidogrel with the goal of continuing DAPT for at least
one year. From the cardiac perspective, the patient received initial
clearance for commercial driving, though he was scheduled to
undergo a formal visual field testing prior to definitive clearance.
Comments from the Task Force
- While neurologic events during or in the few hours following PCI are usu-
ally related to the procedure itself (e.g. due to embolization related to
catheter manipulation in the aortic arch, thrombus formation on the guid-
ing catheter or wires or at the time of thrombus aspiration), in the case
described here the delay is too long to postulate a direct link with the
coronary procedure. The likely explanation for the stroke was detected
earlier that day: a suspected LV apical thrombus on TTE. However, this
finding did not prompt immediate full anticoagulation as it should have.
- The case nicely depicts the challenges of acute stroke treatment in
patients on antiplatelet agents. Current evidence suggests that IV
thrombolytic therapy in patients on a single antiplatelet drug is possibly
associated with a small increase in the risk of intracranial haemorrhage,
while, in the presence of DAPT, the risk is probably higher. However,
current stroke guidelines estimate as likely that the small increased risk
of intracranial haemorrhage in antiplatelet drug users suffering acute
stroke is outweighed by a larger benefit from thrombolysis. Therefore,
it is estimated that there is an overall net improvement in functional
outcomes in pre-stroke antiplatelet drug users treated with IV throm-
bolytic agents.18
- In the described patient, the switch from ticagrelor to clopidogrel fol-
lowing stroke was achieved without administering a clopidogrel loading
dose. The need to concomitantly initiate full anticoagulation for the sus-
pected LV thrombus may have motivated this choice. However, with
respect to the modality of switching from ticagrelor to clopidogrel, the
2017 ESC DAPT Focused Update recommends to load the patient
with 600 mg of clopidogrel 24 hours after the last ticagrelor dose, while
in the present case clopidogrel was restarted at 75 mg/day (see chapter
3.8 in full text document). This may have exposed the patient to an
increased risk of ST, especially because aspirin was also discontinued at
the same time.
- Having stopped aspirin it seemed also reasonable to avoid a potential hae-
morrhagic transformation of the stroke area. Priority was given to an
immediate full anticoagulation with enoxaparin while warfarin was getting
fully effective. According to the 2017 ESC DAPT Focused Update, dual
therapy with clopidogrel 75 mg/day and OAC should be considered as an
alternative to one-month triple antithrombotic therapy (aspirin, clopidog-
rel, and OAC) in patients in whom the bleeding risk outweighs the ischae-
mic risk (see chapter 7.2 in full text document).
- With respect to the duration of anticoagulation for LV thrombus in the
setting of acute MI, the 2017 ESC STEMI guidelines give a consensus of
an expert-type of recommendation, in the absence of dedicated trials,
stating that in patients with LV thrombus anticoagulation should be
administered for up to six months, guided by thrombus resolution on
repeated imaging. In the patient described, after stopping OAC, aspirin
was added to clopidogrel. An alternative option would have been to
restart the initial DAPT, namely aspirin and ticagrelor. While both
options are possible, a more potent platelet P2Y12 inhibitor may have
been considered in case of high ischaemic risk (e.g. multiple stents, left
main [LM] stent, severe three vessel disease, diabetes).
A B
C
Figure 5 Transthoracic echocardiography with evidence of apical
thrombus (A, B). Brain magnetic resonance image showing a small
left occipital infarct area with no signs of haemorrhagic transforma-
tion (C).
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Case #6: Dual antiplatelet therapy
in an elderly man with multivessel
disease treated with coronary
angioplasty
An 81-year-old man was admitted to the emergency room with chest
pain at rest and dyspnoea. Cardiovascular risk factors were notable
for hypertension, dyslipidaemia, type II diabetes, obesity and prior
smoking. This patient, who also had peripheral arterial disease, suf-
fered from NSTEMI treated with multiple stent implantations in the
RCA and left circumflex (LCX) arteries. A few years afterwards, due
to the occurrence of heart failure symptoms, the patient underwent
TTE which demonstrated a slightly reduced LVEF (50%) and a mod-
erate aortic stenosis. At presentation blood pressure was 164/
75 mmHg, heart rate 80 bpm and Sp02 94% in room air. The patient’s
ECG is shown in Figure 6. After implementation of IV nitrates, the
chest pain resolved and a physical examination showed bilateral pul-
monary rales and lower extremity oedema. High sensitivity troponin
I was elevated (4.91 ng/mL). At further laboratory assessment, hae-
moglobin was 10.8 g/dL, haematocrit 31.6% and estimated creatinine
clearance 66 mL/min/1.73m2. GRACE and CRUSADE scores were
170 and 50, respectively, indicating a high risk for both ischaemic and
bleeding complications.
According to our local treatment protocol (Figure 7), this patient
was treated with clopidogrel (the patient was already on aspirin at
presentation) and was then brought to the catheterization laboratory
within 24 hours where a peak-to-peak transaortic gradient of
40 mmHg was measured indicating moderate aortic stenosis, and
stenosis of the ostium of the LAD, proximal and mid RCA. At a fur-
ther Heart Team discussion, the decision was taken to proceed to
PCI with implantation of polymer-free DES in view of the anticipated
need to prematurely stop DAPT due to bleeding. At 6 months
follow-up, no further ischaemic or bleeding episode had occurred, so
DAPT was continued. The case submitter raised a point for discus-
sion: should newer P2Y12 inhibitors have been preferred over clopi-
dogrel in this patient and, more generally, should ticagrelor or
prasugrel be preferred to clopidogrel in patients at both high ischae-
mic and bleeding risks?
Comments from the Task Force
• Patients at both high ischaemic and bleeding risks can encompass
up to 50% of patients in routine clinical practice, which speaks
for the fact that risk factors for recurrent ischaemic events, such
as advanced age and renal dysfunction, overlap with those pre-
dicting bleeding. The assessment of both ischaemic and bleeding
risks in the management of ACS patients is in agreement with
the ESC guidelines, which do endorse, among others, the use of
Global Registry of Acute Coronary Events (GRACE) and Can
Rapid Risk Stratification of Unstable Angina Patients Suppress
Adverse Outcomes With Early Implementation of the
ACC/AHA Guidelines (CRUSADE) scores. However, it should
be emphasized that there is no evidence supporting the use of
these scores to guide P2Y12 inhibitor choice.
• The ESC non-ST elevation acute coronary syndrome (NSTE-
ACS) Guidelines as well as the ESC DAPT Focused Update rec-
ommend more potent P2Y12 inhibitors (ie, ticagrelor or prasu-
grel) to be preferred over clopidogrel in patients with ACS,
whose duration needs to be tailored according to the bleeding
risks.5
• However, the use of prasugrel in patients aged 75 or greater is
relatively discouraged. Moreover, patients judged at high bleeding
risk according to the investigators had to be excluded from par-
ticipation in the TRial to assess Improvement in Therapeutic
Outcomes by optimizing platelet inhibitioN with prasugrel–
Thrombolysis In Myocardial Infarction (TRITON-TIMI 38) where
the superiority of prasugrel over clopidogrel was shown.19
Therefore, it remains unclear if prasugrel should be preferred
over clopidogrel in this high-risk setting. Moreover, since therapy
with a P2Y12 inhibitor was implemented before knowing the cor-
onary anatomy, ticagrelor should have been preferred over pra-
sugrel, as prasugrel is only indicated in ACS patients in whom
coronary anatomy is known and proceed to PCI.
• On the other hand, the benefits of ticagrelor over clopidogrel
were shown to be consistent across age groups and high bleed-
ing risk patients were sizable in the Study of Platelet Inhibition
and Patient Outcomes (PLATO).20 The use of ticagrelor is thus
reasonable in high bleeding risk patients and most likely associ-
ated with better outcomes than clopidogrel. Moreover, in
PLATO ticagrelor was administered upstream, i.e. before know-
ing the coronary anatomy, and could therefore have replaced
clopidogrel without the need to modify the timing of P2Y12
administration. However, it should be noted that no dedicated
study exists comparing ticagrelor over clopidogrel in high bleed-
ing risk patients and patients needing OAC were excluded.
• The Prolonging Dual Antiplatelet Treatment After Grading Stent-
Induced Intimal Hyperplasia Study (PRODIGY) retrospectively
observed that the CRUSADE score could identify patients at
higher risk of haemorrhagic complications when treated with a
two-year DAPT as compared to six-month therapy.21 However,
all patients were treated with aspirin and clopidogrel in both
treatment duration arms so no clear conclusion can be drawn
from this analysis on which P2Y12 inhibitor should be preferred
in high bleeding risk patients. Similarly, only patients without high
bleeding risk features, according to the PREdicting bleeding
Complications In patients undergoing Stent implantation and
subsEquent Dual Anti Platelet Therapy (PRECISE-DAPT) score
(a bleeding risk stratification tool), were shown to derive benefit
from prolonged DAPT as compared to a shorter duration regi-
men.22 Acknowledging that DAPT consisted mainly of aspirin and
clopidogrel, the results of this study remained consistent across
the types of P2Y12 inhibitor. This finding corroborates the notion
that a shorter DAPT duration regimen is preferable over a longer
course of treatment in high bleeding risk patients but it does not
help answer the question of whether clopidogrel or one of the
newer P2Y12 inhibitors is to be preferred in this subpopulation.
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Figure 6 Patient’s electrocardiogram at presentation.
Figure 7 In hospital algorithm for dual antiplatelet therapy selection by Berenguer-Jofresa et al. CRUSADE = Can Rapid Risk Stratification of
Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; GFR = glomerular filtration rate;
GRACE = Global Registry of Acute Coronary Events; PCI = percutaneous coronary intervention.
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..Case #7 Nasal bleeding and dual
antiplatelet therapy
An 82-year-old woman with multiple comorbidities was admitted to
an outpatient clinic because of epistaxis. She also suffered in the days
before from uncontrolled hypertension, recurrent chest pain and
transient neurological symptoms including possible retrograde amne-
sia. She had known hypertension, hyperlipidaemia and chronic stable
angina. Eight years before presentation, she underwent coronary
angiography, which showed normal LV systolic function and three-
vessel CAD for which coronary artery bypass grafting (CABG) was
indicated. She refused CABG surgery and was managed conserva-
tively with a DAPT regimen consisting of aspirin 100 mg/day and clo-
pidogrel 75 mg/day, a beta-blocker, a nitrate, an ACE inhibitor, a
statin and a calcium channel blocker. Since this medical regimen was
implemented, the statin and clopidogrel were transiently stopped
and then restarted on two different occasions based on first disap-
pearance and then recurrence of anginal symptoms.
Anterior nasal tamponade was performed to control the epistaxis.
Therapy with diuretics was also implemented to better control blood
pressure levels. A neurology consultation excluded acute neurologi-
cal disease. Epistaxis, uncontrolled hypertension and recurrent angina
symptoms continued for an additional two to three weeks. ACE
inhibitors and diuretics were up titrated. Following on from an oto-
rhinolaryngology consultation, treatment with anti-histamines for a
few days was also implemented.
Laboratory examinations (e.g. haemoglobin 13.5 g/dL; platelet
count 179 000/mL; creatinine 88.8 mmol/L) and cardiac findings,
including a TTE and ECG (Figure 8) were unremarkable at the time of
presentation.
Since the epistaxis persisted despite clopidogrel discontinuation,
aspirin was also discontinued and concomitant therapy with trimeta-
zidine was implemented, which resulted in no further episodes of
epistaxis. Aspirin was then restarted a few weeks thereafter and con-
tinued throughout, without further recurrences of bleeding.
Comments from the Task Force
- This case provides opportunity for further clarifications on the cur-
rently approved DAPT indications in patients with stable CAD.
Patients with stable CAD have a class I indication for DAPT if
percutaneous revascularization is implemented. With respect
to CABG, there is no convincing evidence for DAPT in the postoper-
ative phase to prevent graft failure. Finally, there is no evidence
to support DAPT in patients with stable CAD treated
conservatively, as in the patient described here. This is at variance
with patients presenting with ACS in whom indication for DAPT
exists irrespective of the concomitant revascularization procedure
and type thereof.
- This patient self-presented to an emergency room with complaints
notable, among others, for epistaxis. However, the previously imple-
mented DAPT regimen was not immediately discontinued, which may
have contributed to the persistence of symptoms. Given the well-
known association between use of anti-thrombotics and bleeding,
including epistaxis,23 and considering the lack of evidence in support of
a DAPT regimen for this specific indication,24,25 immediate discontinua-
tion of one antiplatelet agent would have been indicated. Hence, the
final decision to leave this patient on aspirin monotherapy is entirely
justified.
- After managing the acute bleeding with nasal tamponade, a first attempt
to prevent recurrences by lowering arterial blood pressure levels was
made. Interestingly, it is still doubtful whether a connection exists
between epistaxis and hypertension.26 The prevalence rates of hyper-
tension among patients with epistaxis range from 17% to 67%.27
However, it is a subject of longstanding controversy whether there is
solely an association or cause and effect relationship between hyperten-
sion and epistaxis.26
- Finally, there is no evidence that a DAPT regimen can act by improving
anginal symptoms. Hence, if there are recurrent or worsening angina
symptoms limiting quality of life despite optimization of anti-anginal
medications, a repeat coronary angiogram and revascularization should
be considered.
Figure 8 Patient’s electrocardiogram at presentation.
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Case #8: Dual antiplatelet therapy
reveals what the eye cannot (yet)
see
A 75-year-old smoker with untreated hypertension and hypercholes-
terolaemia presented with anterior STEMI. The patient mentioned
that three months earlier he had reddish coloured urine for 2 - 3 days
without fever or dysuria, but he did not seek medical advice as the
condition resolved spontaneously. As soon as the STEMI diagnosis
was made, the patient received aspirin 250 mg IV, ticagrelor 180 mg,
enoxaparin 4000 units IV, pantoprazole 40 mg, and atorvastatin
80 mg. While waiting for the catheterization laboratory room to be
free, the patient underwent TTE showing a moderate reduction in
LV systolic function (LVEF 35 - 40%) in the presence of anterior aki-
nesia. Using right radial access, the patient underwent primary PCI of
a critical proximal LAD lesion treated with one everolimus-eluting
stent (3.5 x 48 mm) and the clinical course was uneventful (Figure 9).
The patient was discharged on day 5 on aspirin 100 mg/day and tica-
grelor 90 mg b.i.d. in association with other secondary prevention
medications. On day 8, he was readmitted for macro-haematuria. His
systolic blood pressure was 95/55 mmHg, heart rate 90 bpm, haemo-
globin level was 8.4 g/dL and haematocrit 30.1%. Bladder ultrasound
detected two lesions and raised suspicion for cancer. Aspirin was
continued, ticagrelor was discontinued and enoxaparin 4000 units/
day was added by the internal medicine doctors. Two units of packed
red blood cells were transfused. On day 12, haematuria persisted
while the patient was haemodynamically stable and haemoglobin and
haematocrit were 10.4 g/dL and 32.1%, respectively. On day 13, a
urethro-cystoscopy with endoscopic resection of the lesions was
performed. Enoxaparin was stopped 12 hours before the interven-
tion while aspirin was continued. Two hours post intervention, tirofi-
ban infusion was started with a bolus dose of 0.4 mg/kg/min in 30 min,
followed by a maintenance infusion of 0.1 mg/kg/min. He had no
recurrence of haematuria and on day 14 haemoglobin was 11.4 g/dL
and haematocrit 34.1%. The same day ticagrelor was administered
with a loading dose of 180 mg and continued with 90 mg b.i.d., and
after two hours the tirofiban infusion was stopped. On day 28, while
the patient remained asymptomatic, a non-invasive, high-grade blad-
der cancer, with multiple sessile, micro-papillary lesions was con-
firmed. It was recommended to perform a radical resection of the
bladder as soon as possible and in any case within 90 days to improve
survival. On day 38, surgery was performed. Aspirin was continued
while ticagrelor was discontinued five days before surgery. Tirofiban
infusion was started 24 hours post-ticagrelor discontinuation (i.e.
four days before surgery) with a bolus dose of 0.4 mg/kg/min in
30 min, followed by a maintenance infusion of 0.1 mg/kg/min.
Tirofiban was stopped four hours before surgery and restarted two
hours after surgery, with the same bolus and maintenance doses. In
the absence of bleeding, 12 hours post-surgery ticagrelor was admin-
istered with a loading dose of 180 mg and continued with a mainte-
nance dose of 90 mg b.i.d. intended for a total of 12 months post PCI.
Two hours after the ticagrelor bolus the tirofiban infusion was dis-
continued. The postoperative course was uneventful and at his last
follow-up at nine months post PCI the patient was still on DAPT and
had no bleeding or ischaemic events.
Comments from the Task Force
- As a general rule, management of patients on DAPT who are referred
for surgical procedures involves consideration of: (1) the risk of ST (par-
ticularly if DAPT needs to be interrupted); (2) the consequences of
delaying the surgical procedure; and (3) the increased intra- and peri-
procedural bleeding risk and possible consequences of such bleeding if
DAPT is continued. Given the complexity of these considerations, a
multidisciplinary approach, involving interventional cardiologists, cardi-
ologists, anaesthetists, haematologists and surgeons is required to
determine the patient’s risk for bleeding and thrombosis and to choose
the best management strategy.
- Presenting with STEMI, the patient qualified for DAPT with aspirin and
ticagrelor. The decision to discontinue ticagrelor on day 8 post PCI due
to major urinary bleeding was a difficult one, but reasonable due to the
ongoing bleeding and the fact that most urologists would not perform
urethro-cystoscopy with endocavitary treatment in the presence of
DAPT due to the bleeding risk. However, the patient was at the same
time at very high risk of ST. Accordingly, he had multiple characteristics
that have been associated with ST: recent (< 2 weeks) stent implanta-
tion, clinical presentation (ACS), long stent, cancer, and the need for
surgery. In addition, in the event of ST the consequences would have
been potentially catastrophic based on the stent location (proximal
LAD). Ticagrelor was discontinued five days before urethro-
cystoscopy; in this respect, a shorter duration of discontinuation could
have been an option. Accordingly, the 2017 ESC DAPT Focused
Update document states that ticagrelor discontinuation should be con-
sidered at least three days before surgery.
- At the time of ticagrelor discontinuation the patient received prophylac-
tic enoxaparin in addition to aspirin. While potentially increasing the
risk of bleeding (especially in patients with renal insufficiency, a condi-
tion not mentioned in the case), enoxaparin in prophylactic or thera-
peutic doses is not known to reduce the risk of ST. Therefore, low-
molecular-weight heparins should not be administered under the
expectations that this would mitigate the risk of ST. For patients with a
very high risk of ST, like the one described, the 2017 ESC DAPT
Focused Update states that bridging therapy with IV reversible glyco-
protein inhibitors, such as tirofiban or eptifibatide, may be considered.
The reversible IV P2Y12 inhibitor cangrelor is an appealing alternative,
given the role of P2Y12 inhibition in preventing ST and the quicker offset
of action as compared with tirofiban or eptifibatide. In this setting con-
comitant parenteral anticoagulation therapy in conjunction with glyco-
protein inhibitors or cangrelor is not recommended. In the case
described, tirofiban was not administered before the urologic proce-
dure but thereafter, for 24 hours, before restarting ticagrelor.
- Following the results of a biopsy showing cancer, it was decided to per-
form a cystectomy on day 38 post PCI. The pros and cons of having an
early vs. delayed surgery have to be discussed on a case by case basis.
This time the investigators implemented a full bridging (i.e. before and
after surgery) with tirofiban. It has to be noted that the risk of ST by
DAPT discontinuation decreases after the first month post PCI.
Whenever possible, at least one month of DAPT should be adminis-
tered after stent implantation, independently of the type of device (i.e.
BMS or newer generation DES). If surgery has to be performed within
the first month after PCI, the operation should take place in hospitals
where cardiac catheterization laboratories are available 24/7 in order
to treat patients immediately in case of perioperative ST. In patients at
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high ischaemic risk due to ACS presentation or complex coronary
revascularization procedure, delaying surgery up to six months after
ACS or PCI may be reasonable as a safeguard to minimize the risk of
perioperative MI
Case #9: A case with very late
stent thrombosis 20 months after
implantation of a biodegradable
polymer sirolimus-eluting stent
A 56-year-old man presented with NSTEMI (peak troponin T
9.24 mg/L). Coronary angiography showed total occlusions of the
proximal LCX and proximal LAD with a collateral flow from the
RCA and septal branch to the distal LAD (Figure 10A). Two biode-
gradable polymer sirolimus-eluting stents (BP-SES, Orsiro 3.5 x
15 mm and 3.0 x 15mm) were deployed in the LCX (Figure 10B), and
two additional BP-SES (3.0 x 26 mm and 2.5 x 40 mm) were used to
treat the LAD one month after the index procedure (Figure 10C,D).
Maintenance DAPT (aspirin 100 mg q.d. and ticagrelor 90 mg b.i.d.
mg) was prescribed for 12 months, followed by life-long aspirin
monotherapy. The patient presented with antero-lateral (Figure 10E)
STEMI 20 months after the first stent implantation (peak troponin T
3.9 mg/L). Angiography revealed very late ST in the LAD (Figure 10F).
Optical coherence tomography (OCT) after a low-pressure dilata-
tion using a 2.5 mm balloon was performed to assess underlying
mechanisms of very late ST. While the stent struts were well
apposed proximally and distally to the thrombosed region (Figure
10G, J), a positive remodelling with enlargement of the adventitia (4.9
x 4.3 mm, Figure 10H, arrows) was observed. Apposition status of the
struts could not be assessed due to the massive superimposed
thrombus. Focal signs of evagination at the proximal edge of the posi-
tively remodelled segment were also observed (Figure 10 I, asterisk).
Very late ST occurred 20 months after the implantation of a newer-
generation DES with biodegradable polymer, with evidence of posi-
tive remodelling, even on the maintenance aspirin monotherapy fol-
lowing 12 months of DAPT. How should DAPT be managed in this
patient?
Comments from the Task Force
An extraordinary amount of scientific scrutiny has been devoted to
the safety profile of first and newer generation DES. First generation
DES have been consistently shown to be associated with a four- to
five-fold higher risk of very late (i.e. after the first year) ST as com-
pared to BMS.28–31 This observation corroborated the perception of
increased thrombogenicity of DES as compared to BMS and fuelled
‘the longer the better’ notion for DAPT duration in DES treated
patients.
- First generation DES have been entirely replaced by newer generation
devices. Evidence of superior safety with respect to ST and target vessel
MI has been generated for many of the newly introduced devices when
compared to first generation DES.28 There is a growing literature sug-
gesting that at least some second generation devices are safer not only
when compared to first generation but also to the corresponding BMS
counterparts.32,33 As a result, it is relatively rare (unlike for first genera-
tion DES) to observe a very late ST after newer generation DES. Unlike
the vast amount of rigorous statistics generated around the incidence
and distribution of ST events over time after first generation devices,
there are no randomized data to inform on the best management strat-
egy for patients presenting ST, especially very late events. Available find-
ings suggest a high risk for ST recurrences after the occurrence of first
ST, with one patient in every four experiencing a recurrent event at the
five-year time frame.34
- A second key piece of information is that the risk for recurrence is high-
est in the first few months after the first event, but it does not abate
entirely over time. A recent study extending over five years suggests
that roughly 50% of events are clustered within the first year after the
first ST whereas the remaining 50% of events occur from the second up
to the fifth year of follow-up.35–38 This observation carries important
implications with respect to the duration of secondary preventive
measures in this small yet very high-risk patient population.
- All attempts should be made to retrieve all possible drivers for ST, includ-
ing inspection of the index procedure and careful assessment of the
patient’s history focusing on adherence to antiplatelet therapy. Since stent
underexpansion or undersizing is known to frequently contribute to ST,
optimal, ideally imaging-guided, further expansion of the originally
implanted stent is frequently indicated beyond vessel recanalization.37
Considering the long-term risk of recurrent ST after first ST event, any
effort to maintain DAPT at very long-term or even lifelong, if tolerated.
Since very late ST occurred in this patient months after DAPT discontinu-
ation, and considering the uneventful outcome while the patient was still
on DAPT, it may be reasonable to re-implement the previously adminis-
tered P2Y12 inhibitor. As was frequently the case for first generation DES,
especially the Cypher sirolimus-eluting stent, evidence for (most likely
acquired) positive remodelling of the vessel is provided here for the
thrombosed segment. Should this mechanical issue also be tackled during
re-intervention? There is unfortunately no proper guidance from the
available literature. However, it is widely accepted that any effort should
be made to expand the stent as much as is deemed safe.37 Whether re-
implantation of a second stent may help in trying to exclude the enlarged
and widely remodelled vessel area and, by doing so, minimize the stagna-
tion of flow and subsequent thrombosis is unknown, yet frequently per-
formed in practice.37,38 The presence of positive remodelling, which will
likely not be entirely removed or corrected at re-intervention, reinforces
the importance of prolonging DAPT as much as tolerated.
A B
Figure 9 Angiogram showing critical lesion of a proximal left
anterior descending coronary artery (A) treated with primary per-
cutaneous coronary intervention and implantation of one everoli-
mus-eluting stent (B).
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..Case #10: Prolongation of dual
antiplatelet therapy after stent
implantation for ST-elevation
myocardial infarction
A 51-year-old woman with prior STEMI was evaluated at
12 months after the index event. Risk factors at the time of
primary PCI included prior smoking (40 cigarettes/day), hyperten-
sion and poorly controlled diabetes mellitus. Creatinine clearance
was 68 mL/min. The STEMI was due to an acute occlusion of the
distal LM/ostium of the LAD (Figure 11). A self-expanding nitinol
sirolimus eluting stent (3.0 - 3.5 x 22 mm) was implanted from the
LM into the proximal LAD (Figure 12). The stent struts lying in
front of the LCX artery ostium were fenestrated by inflating a
semi-compliant balloon (Figure 12). Finally, a second sirolimus
Figure 10 Coronary angiography showing total occlusions of the proximal left circumflex coronary artery and proximal left anterior descending
coronary artery (A) treated with coronary stent implantation (B, C, D). Electrocardiogram showing ST segment elevation 20 months after first inter-
vention (E) due to very late stent thrombosis confirmed at angiography (F). Optical coherence tomography showed good apposition of stent struts
proximally and distally to the thrombosed region (G, J), positive remodelling (H, arrows) and focal signs of evagination at the proximal edge of the
positively remodelled segment (I, asterisk).
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eluting stent (3.0 x 24 mm) was implanted in the proximal LAD in
overlap with the first implanted stent, with a good angiographic
result (Figure 12). Echocardiography during the hospital stay
showed a mildly impaired LVEF (45%). The patient was discharged
after eight days on DAPT with aspirin (100 mg daily) and ticagrelor
(90 mg b.i.d.) for 12 months, atorvastatin, ACE inhibitor, beta-
blockers and metformin. Thereafter, the patient remained asymp-
tomatic. The patient’s relatives referred good adherence to the
medical treatment and cessation of cigarette smoking. Laboratory
testing showed stable renal function and no anaemia.
The calculated DAPT score at 12 months was 3 (Figure 13), sug-
gesting a higher ischaemic vs. bleeding risk profile. Given the multi-
ple ischaemic risk factors (clinical features resembling Prevention
of Cardiovascular Events in Patients With Prior Heart Attack
Using Ticagrelor Compared to Placebo on a Background of
Aspirin-Thrombolysis in Myocardial Infarction 54 [PEGASUS-TIMI
54] trial inclusion criteria) and the acute clinical presentation for
the index event, the decision was taken to continue DAPT with
aspirin and ticagrelor 60 mg b.i.d. for an additional 12 months.
Comments from the Task Force
- The DAPT score is a new standardized tool aiming at identifying which
patients would derive benefit or harm from a prolonged duration of
DAPT.39 The DAPT score integrates ischaemic and bleeding risk
factors, in order to guide patient selection for optimal DAPT duration
in patients who received DAPT for one year after PCI, and were free
from ischaemic as well as bleeding events. The score ranges from -2 to
10 and is calculated by assigning points according to characteristics
related to the patient (0 for age < 65 years, -1 for age >_ 65 and
< 75 years, -2 for age >_ 75 years, 1 for diabetes mellitus, 1 for current
smokers, 1 for previous PCI or prior myocardial infarction, 2 for history
of congestive heart failure or LVEF < 30%) and the index procedure (1
for acute MI at presentation, 2 for PCI of saphenous vein graft, 1 for
implantation of paclitaxel-eluting stent, 1 for stent diameter < 3 mm).
Overall, a low DAPT score (< 2) identifies patients for whom bleeding
risks outweigh ischaemic benefits, while a high DAPT score (>_ 2) identi-
fies patients for whom ischaemic benefits outweigh bleeding risks. The
score is available on the website at http://www.daptstudy.org/for-clini
cians/calchome.htm.
- The 2017 ESC Focused Update states that the DAPT score may be
used to guide duration of treatment. While it remains unclear whether
the routine use of this score improves patient outcomes, this document
endorses its use on the basis that, together with PRECISE-DAPT, it is
the only available scoring system which has been developed deliberately
with this aim. Additionally, it may help clinicians focusing on the patients
and procedural characteristics most likely to derive benefit or lack
thereof from a prolonged DAPT treatment in an a priori selected group
of patients, which the case just described belongs to.
A B
C
Figure 11 Thrombotic occlusion at the ostium of the left anterior descending coronary artery (A, B, C).
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Figure 12 Primary percutaneous coronary intervention. Balloon inflation (A) is used to restore minimal flow in the left anterior descending coro-
nary artery (B, C, D). A self-expanding sirolimus-eluting nitinol stent is placed and implanted at the distal segment of the left main in the direction of
the left anterior descending coronary artery (E). A second sirolimus eluting stent is implanted distally with minimal overlap (G, H, I). Fenestration of
the stent struts in the left main towards the circumflex artery (L). Final angiographic result (M, N).
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Case #11: Ischaemia and bleeding
in a young patient: between a rock
and a hard place
A 41-year-old man was transported to the emergency department
for continuous and oppressive chest pain associated with nausea and
vomiting lasting for six hours. His only cardiovascular risk factor was
diabetes mellitus treated with insulin. The ECG showed ST-segment
elevation in the anterolateral leads and ST-segment depression in the
inferior leads. The patient was haemodynamically stable (blood pres-
sure 147/102 mmHg; heart rate 90 bpm; SaO2 100%), with no signs
of heart failure. Antiplatelet therapy (aspirin 300 mg and clopidogrel
300 mg) as well as heparin were administered while the patient was
transferred to the catheterization laboratory for primary revasculari-
zation. A coronary angiogram performed from the right femoral
approach revealed a thrombotic occlusion at the ostium of the LAD,
which was treated with mechanical thrombectomy and PCI with
zotarolimus eluting stent implantation (Figure 14). Vascular closure
was obtained with a closure device. At this time, clopidogrel was
switched to ticagrelor (180 mg loading dose administered in the cath-
eterization laboratory).
On day 2, TTE was performed showing akinesia of the anterior
mid-apical segments and a large apical thrombus (22 x 23 mm); for
this reason, oral anticoagulation with acenocoumarol on top of low
molecular weight heparin was started. Ticagrelor was discontinued
and clopidogrel 75 mg q.d. was initiated the same day.
On day 4, the patient remained asymptomatic but routine blood
tests revealed a reduction of approximately 5 mg/dL of the haemo-
globin level. CT showed a right retroperitoneal haematoma and per-
sistence of a large thrombus in the LV (Figure 15). Since the LV
thrombus was deemed not to be immediately life-threatening, a con-
servative management with anticoagulation discontinuation (both
low molecular weight heparin and acenocoumarol) and IV iron sup-
plementation was selected, while DAPT was maintained. On day 8
the patient experienced a new episode of central crushing chest pain.
An ECG revealed recurrent ST-segment elevation in the anterior
leads and the patient was emergently transferred for coronary
angiography. The angiogram performed via the radial approach
showed acute ST at the ostium of the LAD (Figure 16). Mechanical
thrombectomy and balloon angioplasty restored Thrombolysis In
Myocardial Infarction (TIMI) grade III coronary flow. Unfortunately, at
the end of the procedure, after removal of the radial vascular access,
a second episode of chest pain and ST segment elevation on lateral
leads occurred. The left femoral approach was then used, and a coro-
nary angiogram showed recurrent ST protruding into the distal LM
bifurcation with the LCX, with a TIMI grade I flow (Figure 17). An
abciximab bolus was administered and mechanical thrombectomy of
Figure 13 Dual antiplatelet therapy (DAPT) score calculation using the dedicated web-based calculator.
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both the LAD and circumflex arteries was performed. However,
due to the persistence of flow limiting thrombus in the circumflex
artery, the distal LM was approached with bifurcation stenting
(mini-crush technique) with two zotarolimus eluting stents. The
intervention was concluded with a final kissing-balloon, and a
good angiographic result (Figure 17). After the intervention, the
patient was treated with aspirin, ticagrelor and acenocoumarol
with strict international normalized ratio (INR) monitoring.
Hospital stay was further complicated by a mesenteric emboliza-
tion, which was treated conservatively without sequelae. The
patient showed a slow but continuous improvement of the clinical
condition in the following weeks. At the time of discharge, TTE
demonstrated complete resolution of the apical thrombus. The
patient was discharged on triple therapy while acenocoumarol dis-
continuation was planned in the weeks to come.
Comments from the Task Force
This challenging case raises several points for discussion.
- First, the need to de-escalate the type of P2Y12 inhibitors, i.e. from more
potent prasugrel or ticagrelor to clopidogrel, in order to accommodate
the initiation of oral anticoagulation is not infrequent. The 2017 ESC
DAPT Focused Update recommends to switch from ticagrelor to clopi-
dogrel by administering a 600 mg loading dose of clopidogrel, both in
the acute and chronic setting (see chapter 3.8 in full text document).
This in order to avoid a lack of proper platelet inhibition while clopidog-
rel has not yet reached a steady state and the effect of ticagrelor is over.
The mentioned state may have contributed to the occurrence of suba-
cute ST in this patient, perhaps in conjunction with the suboptimal
stenting technique.
- Given the concerns that treatment with clopidogrel may not suffice
to prevent recurrent ST in this very high risk patient, the decision to co-
administer aspirin, ticagrelor and oral anticoagulation can be justified,
although, as a general rule, triple therapy including ticagrelor or prasu-
grel is not recommended based on safety concerns.
- To minimize the risk of bleeding in relation to such an anti-thrombotic
regimen, the decision was taken to reduce the duration of concomitant
oral anticoagulation, from up to six months as per the ESC STEMI 2017
guidelines recommendations to a few weeks. In order to avoid LV
thrombus recurrence, a close follow-up with TTE (if the ultrasound
window is adequate) or MRI is warranted. Moreover, a longer duration
of OAC in a patient with prior systemic embolization could be envi-
sioned. Possible alternative treatment strategies – even if not evidence
based – would have been the decision to drop aspirin for the period of
time concomitant anticoagulation is administered or to switch the
patient back to clopidogrel by means of a 600 mg loading dose and care-
ful monitoring of the degree of P2Y12 inhibition by platelet function
testing to exclude the possibility that the patient is a poor- or non-
responder to clopidogrel.
- Finally, this case illustrates the advantages of using a radial instead of a
femoral access site.
Figure 14 Coronary angiogram showing thrombotic occlusion of the left anterior descending coronary artery, treated with primary percutaneous
coronary intervention and stenting.
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Figure 15 Computed tomography scan revealing persistence of the apical thrombus (left panel) and right retroperitoneal haematoma (right
panel). Video available online.
A B C
D E F
Figure 16 First stent thrombosis of the device implanted at the left anterior descending coronary artery ostium (A, B). Coronary angiogram and
intervention with thrombus aspiration and balloon angioplasty (C, D, E, F).
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Case #12: Dual antiplatelet
therapy: treatment decision-
making with risk scores after stent
implantation
A 76-year-old woman with stable angina (Canadian Cardiovascular
Society II) and positive stress-echocardiography was referred for cor-
onary angiography. Her medical history included hypertension, dysli-
pidaemia, well-controlled insulin-requiring diabetes mellitus, and
previous smoking (she stopped smoking one year prior to admis-
sion). No prior history of bleeding was reported. TTE revealed pre-
served LVEF (55%) with mild mitral regurgitation. Laboratory data
before admission showed haemoglobin 11.2 g/dL and creatinine
clearance 48 mL/min. A coronary angiogram revealed significant
lesions of the mid-segment of the LAD (Figure 18) and no significant
stenosis on RCA and LCX. She was treated with PCI and implanta-
tion of two overlapping everolimus-eluting stents (3.0 x 18 mm
and 2.75 x 23mm) in the LAD (Figure 18). No complication occurred
during the hospital stay. At discharge her PRECISE-DAPT score was
35, indicating a high risk of bleeding, and three to six months of treat-
ment with clopidogrel on top of life-long aspirin was prescribed
(Figure 19). The patient remained asymptomatic and at three months’
follow-up was free of chest pain and no bleeding events had
occurred. DAPT was than prolonged for three additional months.
Comments from the Task Force
- DAPT with aspirin plus a P2Y12 inhibitor prevents ischaemic events after
coronary stenting, but increases bleeding. Guidelines support weighting
bleeding risk prior to the selection of treatment duration, and PRECISE-
DAPT may be used for that purpose soon after percutaneous interven-
tion to guide DAPT duration.22 The score integrates age, creatinine
clearance, haemoglobin, white blood cell count and prior spontaneous
bleeding, and can be found at www.precisedaptscore.com.
- Selecting upfront a shorter than 12-month treatment duration in
patients, including ACS, deemed at high bleeding risk (PRECISE-DAPT
score >_ 25) was shown retrospectively to prevent exposing them to an
excessive bleeding hazard. In turn, patients at non-high bleeding risk
(PRECISE-DAPT score < 25) might receive a standard (i.e. 12 months)
or a prolonged (i.e. > 12 months) course of treatment if tolerated. It
should be stated, however, that the ESC DAPT Focused Update rec-
ommends six months of DAPT as the standard duration in the case of
PCI, irrespective of stent type used, in patients with stable CAD.
A B C
D E F
Figure 17 Second stent thrombosis of the device implanted at the left anterior descending coronary artery ostium with thrombotic obstruction
of the circumflex artery ostium (A). Bifurcation stenting of the distal left main with mini-crush technique was performed (B, C, D, E) with good result
(F).
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Figure 19 PRECISE-DAPT score calculation using the dedicated web-based tool. PRECISE-DAPT = PREdicting bleeding Complications In patients
undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy. TIMI = Thrombolysis in Myocardial Infarction.
A CB
Figure 18 Elective coronary angiogram revealing long lesion of the mid-segment of the left anterior descending coronary artery (A-B). Optimal
result after percutaneous coronary intervention (C).
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..Case #13: Oral anticoagulation,
triple therapy and complex
percutaneous coronary
intervention
A 78-year-old man was admitted for NSTEMI. His cardiovascular risk
factors included hypertension, hypercholesterolaemia and diabetes
treated with oral hypoglycaemic drugs. He was known for paroxys-
mal atrial fibrillation treated with rivaroxaban 20 mg/day, two pre-
vious strokes, and surgery for diverticulitis 13 years earlier. His
kidney function was normal. He received oral aspirin 200 mg.
Coronary angiography showed a 70 - 90% distal LM bifurcation lesion
and a 70 - 90% severely calcified stenosis of the proximal LAD, in
conjunction with other multiple lesions in the RCA (Figure 20). The
ventricular function was normal. Despite the low CABG mortality
estimated by the Society Of Thoracic Surgery (STS) score (2.4%) and
Euroscore II (2.2%) and the presence of diabetes, the Heart Team
proposed a PCI based on the considerations that the LCX was a
small vessel which could not be bypassed, the RCA branches also
had distal lesions not accessible to surgical revascularization, and the
patient had suffered two previous strokes. These limitations for sur-
gery were weighted, also in the discussion with the patient and his
family, against the fact that he would require multiple stents and was
at the same time on chronic anticoagulation. This put him at
increased ischaemic risk, especially in case of premature platelet
inhibition discontinuation, as well as at increased bleeding risk
because of triple therapy (aspirin, clopidogrel, and anticoagulation)
and a Hypertension, Abnormal Renal/Liver Function, Stroke,
Bleeding History or Predisposition, Labile INR, Elderly, Drugs/
Alcohol Concomitantly (HAS-BLED) score of 3. Using a bilateral
transfemoral approach and intra-aortic balloon counterpulsation
(which may have been avoided to further increase the risk of bleed-
ing), a total of four DES (Biofreedom, Biosensor) were placed in the
RCA and in the PL branch of the same vessel while the posterior
descending artery (PDA) was treated with balloon angioplasty only
(small vessel). Subsequently, after rotablation of the LAD, two
Biofreedom stents were placed in the LM and proximal LAD while
the ostium of the small LCX was treated with balloon angioplasty
only (opening of the struts of the LM struts) (Figure 20). The proce-
dure was uneventful and, in addition to aspirin, the patient received
600 mg clopidogrel loading dose followed by 75 mg/day and rivaroxa-
ban 15 mg/day. He was also put on esomeprazole 40 mg/day for gas-
tric protection. A low residual platelet reactivity was documented by
vasodilator-stimulated phosphoprotein (VASP) (11%) the next day.
The initial plan was to administer triple therapy for six months and
then to stop clopidogrel, while aspirin should have been continued
for one year and lifelong OAC. One month after the procedure, the
patient developed GI bleeding. The minimal haemoglobin level was
6.5 g/dL and he was transfused with two red blood cell concentrates.
Rivaroxaban was put on hold while DAPT continued. Gastroscopy
showed erythematous gastritis without an active source of bleeding.
Colonoscopy showed extensive diverticulosis of the colon thought
to be the source of the bleeding, though also at that level no active
bleeding source was identified. Rivaroxaban was restarted at the
same dosing. Three months after PCI, the patient developed
haematuria. Aspirin was stopped and the patient underwent outpa-
tient cystoscopy. During the filling of the bladder for the cystoscopy,
the patient had a (likely vasovagal) syncope, fell, and suffered a trau-
matic injury of the head. Emergent CT scan showed bilateral post
traumatic subdural and subarachnoid haematomas as well as right
temporal intracerebral bleeding (Figure 21). All antithrombotic treat-
ment was stopped, while for the neurosurgeons there was no indica-
tion to intervene. The patient never recovered and, in addition,
developed pneumonia. He died 12 days after admission.
Comments from the Task Force
This case with a fatal outcome illustrates the challenges of weighting
ischaemic and bleeding risks. The first risk assessment in this case was
with respect to PCI vs. CABG. In the Heart Team discussion, the
increased bleeding risk associated with triple therapy was clearly part
of the equation. Nevertheless, for the reasons mentioned earlier, PCI
was still considered the most favourable option. Multiple questions
related to this come to mind.
Was the intended duration of triple therapy (aspirin,
clopidogrel, anticoagulation) of six months appropriate?
Yes
First of all, we have to admit that a patient like the one described
(NSTEMI, multiple stents including LM stent) would have never been
enrolled in any of the (small) randomized controlled trials that have
addressed this question. The 2017 ESC DAPT Focused Update states
that, although as a general rule in patients undergoing PCI triple ther-
apy should be considered for one month, in patients with high ischae-
mic risk triple therapy for longer than one month and up to six
months should be considered (see chapter 7.2 in full text document).
Was the measurement of P2Y12-mediated residual
platelet function after loading of clopidogrel indicated/
necessary? No
Although the treating physicians likely feared a suboptimal response
to clopidogrel in this diabetic patient with ACS and multiple stents,
including in the LM trunk, no study has ever demonstrated that tailor-
ing clopidogrel dose to residual platelet activity improves patient out-
comes. Therefore, the 2017 ESC DAPT Focused Update does not
recommend assessment of platelet reactivity under DAPT (chapter
3.7 in full text document).
Was the choice of a non-vitamin K antagonist oral antico-
agulant (NOAC) as a component of triple therapy appro-
priate? Yes
Although current recommendations state that both NOAC and
VKAs can be used as components of triple therapy, adequately pow-
ered randomized controlled trials are ongoing; the limitations of the
only trial available (Rivaroxaban and a dose-adjusted oral vitamin K
antagonist treatment strategy in subjects with atrial fibrillation who
undergo percutaneous coronary intervention [PIONEER-AF-PCI])40
are described below.
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..Was the dose of rivaroxaban (15 mg/day) appropriate?
Not sure
This dose has compared favourably vs. warfarin in terms of bleeding
in patients exposed to triple therapy (unlike rivaroxaban) in the
PIONEER-AF-PCI trial.40 However, the study was not powered to
address ischaemic endpoints, notably ischaemic strokes. Therefore, it
is not known whether the 15 mg/day dose of rivaroxaban with or
without associated antiplatelet agents confers adequate protection
against stroke, as it has never been tested in an adequately powered
trial in this context. Accordingly, the 2017 ESC DAPT Focused
Update gives only a weak recommendation (IIb) for this dosing, stat-
ing that when rivaroxaban is used in combination with aspirin and/or
clopidogrel, rivaroxaban 15 mg/day may be used instead of rivaroxa-
ban 20 mg/day. In the case of this patient the 15 mg dose was a "tough
call" because he was also at very high risk of embolic stroke (two pre-
vious strokes and a CHA2DS2-VASc score of 7).
Was the choice of the Biofreedom stent appropriate? Yes
The Biofreedom stent is the only stent currently on the market that
has been adequately tested in a population of patients at high bleeding
risk. In the Prospective randomized comparison of the BioFreedom
biolimus A9 drug-coated stent versus the gazelle bare-metal stent in
patients at high bleeding risk (LEADERS-FREE) study, among 2466
patients at high bleeding risk (27% of them with ACS) receiving
DAPT with aspirin and clopidogrel for four weeks followed by aspirin
alone, randomization to the drug-coated stent Biofreedom, as com-
pared with its BMS version, was associated at one year not only with
a reduction in clinically driven target lesion revascularization (as
expected) but also a reduction in the primary safety endpoint of
cardiac death, MI, or ST.14 In particular, no difference in ST was
observed. Having said that, the 2017 ESC DAPT Focused Update rec-
ommends second generation DES over BMS also in patients at high
bleeding risk without differentiating one device from the other.
Was the choice of a transfemoral approach for the PCI
according to current recommendations? No
Current recommendations clearly favour routinely the transradial
approach over the transfemoral one for PCI as this is associated not
only with a reduction in major bleeding but also in mortality.41
However, in this case the operator chose the transfemoral access
because of a larger bore catheter (7 French) for the rotablation of
the LAD and the treatment of the LM trunk. In addition, an additional
contralateral femoral approach was used for intra-aortic balloon
counterpulsation. Finally, the operator obtained also femoral venous
access so if needed central venous access was available of vasopres-
sor administration and, in case of major haemodynamic compromise
or complication using existing femoral arterial and venous accesses
the patient could be rapidly assisted with one extracorporeal mem-
brane oxygenation (ECMO).
Was the fatal event related to the antithrombotic
treatment? Yes, though indirectly
On the one hand, the potent antithrombotic regimen favoured the
extensive intracranial bleeding following the trauma. On the other
hand, the trauma occurred accidentally as the patient was being
investigated for a macro-haematuria, the latter also favoured by the
triple therapy.
A B
C D E
Figure 20 Coronary angiography showing a 70 - 90% distal left main (LM) bifurcation lesion (A), a 70 - 90% severely calcified stenosis of the proxi-
mal left anterior descending artery (LAD) (B), and multiple lesions at the level of the right coronary artery (RCA) as well of the large posterior lateral
artery (PLA) and of the small posterior descending artery (PDA) (C). Intervention with stent implantation in the LM and proximal LAD (D) and RCA
(E).
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Case #14: Periprocedural
myocardial infarction in elective
percutaneous coronary
intervention: when stenting goes
wrong, dual antiplatelet therapy
should be strong
A 55-year-old man with a history of hypertension and active smoking
was admitted for an elective coronary angiogram because of stable
angina with a positive stress test. He was overweight (body mass
index = 32 kg/m2) and sedentary. Low-density lipoprotein choles-
terol was 210 mg/dL and glycated haemoglobin 7.6%, showing undiag-
nosed diabetes. He received a loading dose of aspirin the day before
the angiogram and 600 mg of clopidogrel during the procedure. The
coronary angiogram revealed a significant stenosis of the distal LM
coronary artery and proximal circumflex coronary artery (Figure
22A). Ad hoc PCI with a DES implanted from the LM to the circum-
flex artery was performed with the symptomatic loss of a small
obtuse marginal branch (Figure 22B), requiring the use of IV pain relief
drugs. Periprocedural MI (type 4a) was confirmed by a rise of high
sensitive cardiac troponin up to 1450 ng/L (N < 14 ng/L). He was dis-
charged the day after on DAPT with clopidogrel and aspirin.
Ten days later, the patient was admitted for cardiogenic shock due
to thrombosis of the LM stent (Figure 22C) and treated successfully.
Clopidogrel was then switched to ticagrelor and the patient was dis-
charged with DAPT for a year.
Comments from the Task Force
There are several points to be highlighted according to the recent
DAPT Focused Update.
i. In the case of complex anatomy in stable patients (even more so in
patients with diabetes mellitus), a Heart Team discussion should
always guide the decision-making (i.e. PCI vs. CABG). This may have
allowed an oral P2Y12 receptor to reach steady state before PCI was
undertaken (see below). Specifically, ad hoc intervention for LM
stenosis (as well as for complex multi-vessel disease) in stable
patients is highly discouraged by guidelines since it prevents a proper
Heart Team discussion and transparent patient counselling about the
pros and cons of each revascularization technique.
ii. Pretreatment with P2Y12 receptor inhibitors in this elective PCI
should also be discussed. The likelihood of coronary intervention
was high in the present case. A strategy of P2Y12 pretreatment prior
to the diagnostic coronary angiogram may have been considered,
although the evidence is not robust.42
iii. The third possible point of discussion is the use of crushed clopidog-
rel tablets. Speeding the onset of P2Y12 inhibition may have avoided
the thrombotic obstruction of the obtuse marginal branch. Delayed
absorption of clopidogrel had most likely occurred in this patient
given that he was laying on his back and the concomitant use of IV
pain relief drugs.43,44
iv. Periprocedural MIs are frequent complications of complex PCI and
are associated with increased mortality.45 There is some evidence
coming from subgroup analyses that more potent P2Y12 inhibitors
(i.e. ticagrelor or prasugrel) are better than clopidogrel even in the
setting of high-risk elective PCI. This strategy of an off-label use of
ticagrelor or prasugrel in elective PCI to avoid periprocedural MI is
currently being tested. For the time being, ESC guidelines state that
ticagrelor or prasugrel may be used in elective PCI only if there is a
prior history of ST while on clopidogrel.
Figure 21 Emergent computed tomography scan showing bilat-
eral post traumatic subdural and subarachnoid haematomas and
right temporal intracerebral bleeding.
ESC Guidelines e23
Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/3/e1/4095045
by E-Library Insel user
on 06 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..Case #15: Spontaneous coronary
artery dissection in a young
woman
A 44-year-old female presented to the emergency room with acute
chest pain accompanied by vomiting and sweating which lasted for
two hours and started after an argument within the family. She had a
history of hypertriglyceridaemia and smoking (20 cigarettes per day);
she had no family history of cardiovascular disease and was not on
oral contraceptives. On admission, she was asymptomatic. An ECG
performed in the emergency room showed a 1 - 2 mm ST-segment
elevation in leads II, III and aVF as well as a 1 - 2 mm ST-segment
depression in leads V1, V2, V3. A repeat ECG at 10 minutes showed
resolution of the ST-segment deviation in all leads, while a negative
T-wave in the inferior leads persisted. The troponin I level was
0.12 ng/mL (ULN: 0.1 ng/ml). The patient was treated with aspirin,
loading doses of 300 mg clopidogrel, and 1 mg/kg enoxaparin subcu-
taneously. On TTE there was the suspicion of posterior hypokinesia
in the presence of normal global systolic function. Coronary angiog-
raphy showed a left coronary artery with no evidence of atheroscle-
rosis. Injection of the RCA showed a dissection involving the ostium
and the proximal portion of the vessel in the presence of normal
flow and no evidence of CAD. There was some evidence of throm-
bus formation at the distal end of the dissection and a subdivision of
the posterolateral branch was occluded by distal embolization (Movie
1). Two DES were implanted at the level of the proximal and mid
RCA. Balloon angioplasty was performed at the level of the subdivi-
sion of the posterolateral branch with a good angiographic result
(Movie 2). The ECG post procedure was unchanged. Troponin I
increased to a peak level of 14.96 ng/mL. The patient was treated
with aspirin and beta-blockers, the clopidogrel was switched to tica-
grelor (no loading dose), and she was discharged on day 8. The
intended DAPT duration was one year.
Comments from the Task Force
- This patient had spontaneous coronary artery dissection, a condition
that affects women in over 90% of cases. As in the presented case, a
precipitating emotional or physical stress may be identified in the major-
ity of patients. In a recent prospective series of 168 spontaneous coro-
nary artery dissection patients who underwent imaging screening of
renal, iliac, and cerebrovascular arteries performed with angiography or
CT angiography/MR angiography, fibromuscular dysplasia was identified
in 72% of the cases.46 The young patient described here presented with
transient inferior ST-segment elevation and reciprocal ST-segment
depression in the anterior leads and, therefore, qualified for immediate
coronary angiography and DAPT with aspirin and either ticagrelor or
prasugrel, administered as a loading dose in the emergency department
or before PCI.
- The decision to proceed to revascularization in spontaneous coronary
artery dissection patients is very challenging and based on limited data.
Revascularization by PCI or CABG (the latter to be considered mainly
in the case of LM trunk involvement) is indicated if the patient has
ongoing ischaemia involving a major coronary territory or recurrent
ACS episodes on maximal medical treatment. In the absence of ongoing
ischaemia, and independently of how ugly the coronary artery looks on
angiography, a conservative approach is favoured.
- In the case presented, the operators decided to treat the patient by PCI,
with an excellent final result. However, a conservative strategy could
have also been proposed, as the patient had no pain/ECG changes at
the time of angiography, and had only the (embolic) occlusion of a side-
branch of the posterolateral branch of the RCA while the flow in the
remaining territory of the RCA was normal. In addition, the dissection
started at the ostium and the true lumen could not be easily identified -
both risk conditions for an abrupt occlusion during PCI. While intravas-
cular imaging with ultrasound or OCT can elegantly confirm the diagno-
sis of coronary dissection and document the extension of the disease,
invasive imaging should be considered only if the decision to proceed to
revascularization has already been made, because any attempt to
undertake intravascular imaging could trigger abrupt vessel closure. A
recent series on 189 spontaneous coronary artery dissection patients
described a failure rate of approximately 50% among patients who
underwent PCI. The same degree of failure was also observed in the
subgroup with normal coronary flow at baseline, while 13% of the latter
required emergency CABG following PCI.46
Figure 22 Coronary angiogram revealing a significant stenosis of the distal left main coronary artery and proximal circumflex coronary artery (A).
The patient was treated with ad hoc percutaneous coronary intervention with a drug-eluting stent (B). Subacute stent thrombosis of the left main
stent (C).
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- With respect to DAPT, aspirin and ticagrelor (or prasugrel) for one
year followed by aspirin alone seems reasonable following DES implan-
tation for the treatment of ACS, even if not caused by CAD. According
to the 2017 ESC DAPT Focused Update, switching from clopidogrel to
ticagrelor should imply the administration of a loading dose of 180 mg
ticagrelor. With respect to spontaneous coronary artery dissection
patients treated conservatively, there is no sufficient evidence to estab-
lish a formal recommendation on antiplatelet management. One possi-
ble approach is to administer aspirin for at least 12 months and a P2Y12
inhibitor (in most series the administered agent was clopidogrel) for
one to 12 months after the index event.46
Case #16: Platelet reactivity
testing after percutaneous
coronary intervention: caveat
emptor
A 65-year-old Chinese male patient with previous stent implantation
in the mid LAD artery – treatment for an ACS six weeks earlier –
presented with unstable angina pectoris. He was on aspirin and clopi-
dogrel. Coronary angiography revealed a patent LAD stent but
evidence of a filling defect inside the stent suspicious for ST (Movie 3).
Intravascular ultrasound imaging showed stent underexpansion. The
patient underwent repeat percutaneous intervention with implanta-
tion of a new generation DES in the previously treated segment with
a good immediate result (Movie 4). Clopidogrel was switched to tica-
grelor 90 mg twice daily. Platelet function testing two weeks later
showed good platelet inhibition and subsequent follow-up testing on
half and then quarter dose ticagrelor dosing showed stable platelet
inhibition. Five months later the patient re-presented with unstable
angina and a CT coronary angiogram suggested repeat stent occlu-
sion due to restenosis (Figure 23). This was confirmed at coronary
angiography and OCT imaging and treated with implantation of a fur-
ther new generation DES (Figure 24, Movies 5 and 6).
Comments from the Task Force
There are a number of excellent discussion points arising from this
case.
- First, the initial presentation is an ST due to stent underexpansion, a
well-recognized risk factor.47–49 In this case, the patient had been dis-
charged on aspirin and clopidogrel despite stenting in the setting of
ACS. It might be speculated that this event may have been prevented
by guideline-recommended combination therapy of aspirin, prasugrel
or ticagrelor at the time of the first procedure (see chapter 3.6 in full
text document).
- Second, the patient subsequently underwent platelet function testing on
a number of occasions during follow-up. Indeed, on the basis of this, the
intensity of antiplatelet therapy was de-escalated and the dosage of tica-
grelor was successively reduced down to a quarter of the standard
dose. Such an approach is not routinely recommended (see chapter 3.7
in full text document). Indeed, although it has long been known that pla-
telet function testing can identify patients who are at a higher risk of
ST,50 randomized clinical trials have failed to show clinical benefit with
management strategies based on therapy tailored according to the
results of platelet function testing.9–12 Moreover, although a single
recent randomized trial reported that a strategy of de-escalation of anti-
platelet therapy intensity (from a more potent ADP-receptor antago-
nist to clopidogrel a number of weeks after stenting) may be reasonable
in selected patients,51 convincing evidence demonstrating the validity of
this approach is lacking and this strategy cannot be recommended at
present. Third, clinically important differences in terms of the optimal
dosage in patients with Asian ethnicity as compared with Caucasian eth-
nicity must be considered and some randomized trial data exist to sup-
port dose reduction of ADP-receptor antagonists in these patients.52
However, results from PLATO are indeed consistent across geographic
regions, including Asia. Nevertheless, large-scale randomized trial data
are lacking and this issue should be the subject of further study.
Movie 2 Stenting of the proximal and mid right coronary artery
with two drug-eluting stents. The movie file can be found here:
https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/
eurheartj/ehx503#supplementary-data.
Movie 1 Coronary angiography of the right coronary artery
revealing a spontaneous dissection throughout the proximal and
mid parts with no evidence of atherosclerosis. The movie file can be
found here: https://academic.oup.com/eurheartj/article-lookup/doi/
10.1093/eurheartj/ehx503#supplementary-data.
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- A final comment focuses on the implications of three stent layers to
successfully treat this mid LAD lesion. While the evidence is clearly
not conclusive in this regard, observational data suggest that no
attempt should be made to interrupt DAPT treatment in those
patients even remotely from the intervention. In addition, the need
to sequentially stent one coronary lesion three times to achieve
proper revascularization should always prompt considerations in
favour of switching from percutaneous to surgical revascularization
in order to obtain long lasting vessel patency, especially if the LAD is
involved.
Movie 4 Percutaneous intervention with implantation of a new
generation drug-eluting stent in the previously treated segment.
The movie file can be found here: https://academic.oup.com/
eurheartj/article-lookup/doi/10.1093/eurheartj/ehx503#supplemen
tary-data.
Movie 6 Further intervention with implantation of a drug-eluting
stent in the previously treated segment. The movie file can be found
here: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/
eurheartj/ehx503#supplementary-data.
Movie 3 Coronary angiography reveals partial filling defect inside
the stent suspicious for stent thrombosis. The movie file can be
found here: https://academic.oup.com/eurheartj/article-lookup/doi/
10.1093/eurheartj/ehx503#supplementary-data.
Movie 5 Another coronary angiography showing critical stenosis
of the in-stent segment. The movie file can be found here: https://aca
demic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/
ehx503#supplementary-data.
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Figure 24 Optical coherence tomography of the in-stent segment.
Figure 23 Computed tomography coronary angiogram suggests recurrent in-stent restenosis. LAD = left anterior descending; LM = left main.
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Case #17: Antiplatelet therapy
after bioresorbable scaffold
implantation – when is it safe to
interrupt?
A 44-year-old female patient presented with an acute STEMI.
Emergency coronary angiography showed a complete occlusion of
the mid LAD (Figure 25A). Flow was restored with thrombus aspira-
tion, intracoronary nitrate administration and balloon angioplasty.
Two everolimus-eluting bioresorbable scaffolds (Absorb, Abbott
Vascular) were implanted in overlapping fashion (3.0 x 18 mm and 2.5
x 28 mm) in the mid LAD lesion and a third scaffold (2.5 x 18 mm) was
implanted in the distal LAD. The final angiographic result was good
(Figure 25B). The patient was discharged on aspirin and ticagrelor.
Seven months later the patient was re-admitted with subacute genital
tract bleeding requiring transfusion of 3 units of blood in the preceding
weeks and persistent symptomatic anaemia (haemoglobin level was
7.9 g/dL). With a view to assessing the risk of discontinuation of
DAPT, coronary angiography and OCT imaging of the LAD was done.
This revealed a good result in the stented area with good apposition
and coverage of the implanted scaffolds (Figure 26). Ticagrelor was dis-
continued and the patient was discharged on aspirin monotherapy.
Comments from the Task Force
- The optimal duration and intensity of DAPT after implantation of a biore-
sorbable stent (BRS) has not been well studied. The only BRS that has
approval for use and for which there are published randomized clinical
trial data is the Absorb BRS, which was used in this case. Randomized
clinical trials with this scaffold show that at follow-up of nine to
12 months, the risk of ST is approximately two-fold higher with BRS as
compared with conventional newer generation DES.53 Most of this risk
occurs early, within the first month after implantation, and may be related
to suboptimal deployment of the scaffold during the implantation proce-
dure. Moreover, a number of trial reports with longer-term follow-up
suggest some evidence of a second period of risk between one and three
years after implantation,54 and a recent clinical trial including patients
treated in routine practice showed an overall three- to four-fold increase
in ST with BRS at a median follow-up of just over 700 days.55 The reasons
for this late risk are unclear though it may be related to the dismantling of
the scaffold during bioresorption.56 One recent report suggested an
increased risk of scaffold thrombosis in patients who discontinued DAPT
before 18 months.57
- Against this background, and faced with a significant bleeding event at
seven months after stenting, the treating physician in this case has a diffi-
cult choice to make. Ordinarily, 12 months of DAPT would be recom-
mended based on the index presentation with STEMI (class I
recommendation, level of evidence A) (see chapter 4.2 in full text docu-
ment). However, in view of concerns regarding late adverse events
with BRS, many physicians would consider prolongation of DAPT for
two to three years (with the intention to have high platelet inhibition
during the period of scaffold resorption). Indeed, although evidence in
this area is lacking, the Task Force recommends prolongation of DAPT
beyond 12 months in these patients (class IIa recommendation, level of
evidence C) (see chapter 4 in full text document). The decision of the
authors to schedule angiography and OCT imaging in order to assist in
decision-making regarding DAPT can be understood but cannot be
routinely recommended. There are small but defined risks associated
with repeat angiography and invasive imaging. In addition, there is no
evidence to support the discontinuation of DAPT based on, say, a cer-
tain degree of strut coverage or apposition.58 Moreover, not all cov-
ered struts are covered with mature, thrombo-resistant neointima.59
Finally, specifically in the case of BRS, features conferring increased risk
of late adverse events are not well characterized. In particular, the rate
of patients with favourable imaging characteristics at interval imaging is
not known. Nevertheless, in this case, regardless of whether or not sur-
veillance imaging was done, discontinuation of the ADP receptor antag-
onist and continuation of aspirin treatment seems reasonable.
Moreover, it should always be borne in mind that decision-making
regarding DAPT is a dynamic process and should be re-visited after clin-
ical evaluation of the patient during further follow-up.
Figure 25 Emergency coronary angiography showing a complete occlusion of the mid left anterior descending coronary artery (A), which was
treated with implantation of three bioresorbable vascular scaffolds (BVS) with good angiographic result (B).
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Figure 26 Optical coherence tomography at follow-up showing good coverage of the scaffold struts.
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Case #18: Management of dual
antiplatelet therapy in a patient
with a femoral pseudoaneurysm
following percutaneous coronary
intervention
A 72-year-old patient presented with unstable angina and an ECG
revealed significant ST-segment and T-wave abnormalities in the
anterior precordial leads. Coronary angiography revealed a subtotal
stenosis of the proximal LAD (Figure 27A). The patient was treated
with implantation of a BMS (3.0 x 20 mm, PRO-Kinetic Energy,
Biotronik) with a good immediate result (Figure 27B). The post-
procedural course was complicated by pseudoaneurysm formation
at the site of the right femoral arterial puncture (Figure 28). On day
10, the patient underwent operative repair of the pseudoaneurysm
and clopidogrel therapy was interrupted 24 hours in advance of the
procedure. A number of hours after the procedure, the patient
developed anterior STEMI. Repeat catheterization revealed throm-
botic stent occlusion (Figure 29A), which was successfully managed
with balloon angioplasty (Figure 29B).
Comments from the Task Force
- Early ST remains a well-recognized complication of coronary stenting.
Historically, prior to the advent of DAPT, rates of early ST of up to 10%
were reported, despite aggressive anticoagulation with aspirin, heparin,
VKAs and thrombolytic agents.60, 61 However, the demonstration that
DAPT with a P2Y12 ADP-receptor antagonist added to aspirin signifi-
cantly reduced both ST and bleeding was perhaps the critical develop-
ment that facilitated widespread adoption of PCI.62,63 Contemporary
registries show rates of early ST of 0.5% or less.64 Risk factors for early
ST include suboptimal procedural result (e.g. underexpansion), inad-
equate response to antiplatelet therapy, presentation with ACS,
complexity of lesion morphology, reduced LV function, and presence
of diabetes mellitus.48
The presented case contains a number of instructive discussion points.
- First, increasing adoption of transradial PCI has demonstrated an impor-
tant role in improving patient outcomes. Indeed, recent randomized
clinical trial data support improved outcomes in patients treated with
transradial PCI compared with transfemoral PCI and this benefit may be
more pronounced in patients presenting with ACS.41 Successful trans-
radial access in this patient would have prevented this complication.
Nevertheless, transfemoral access remains necessary in certain cases
and is still widely performed as a routine approach in many countries.
- Second, femoral pseudoaneurysm formation is not infrequently encoun-
tered after transfemoral access.65 Optimal management depends on
early diagnosis and prompt treatment. A variety of strategies may be
adopted, ranging from repeat manual compression (better if under ultra-
sound control) to local thrombin injection, to covered stent implantation,
to surgical repair.65 Surgical repair may be favoured based on local anat-
omy or lack of endovascular expertise. If early surgical repair is chosen,
DAPT should be continued. Regardless of the stent implanted, the risk of
ST with interruption of DAPT in the first 30 days after PCI is consider-
able.15 Moreover, surgical intervention promotes a procoagulant
response and further increases the risk of ST. Interestingly there are no
convincing data to suggest that risk of early ST is lower with BMS in com-
parison with current generation DES. In fact, the opposite may be the
case,66 and some experimental work suggests that polymer-coated
stents may be less thrombogenic than uncoated stents in the early
phase.67 For this reason, DES are recommended for use in all clinical sit-
uations and the planned duration of DAPT should be tailored according
to the patient and lesion characteristics, not the type of stent implanted
(see chapter 2.2 in full text document).
- Finally, it is not known whether ST would have occurred had the patient
been treated with a more potent P2Y12-receptor antagonist – the pre-
ferred therapy in patients with stent implantation in the setting of ACS
(see chapter 3.6 in full text document).
BA
Figure 27 Coronary angiography revealing a subtotal stenosis of the proximal left anterior descending coronary artery (A) treated with implanta-
tion of a bare-metal stent with a good acute result (B).
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